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Abstract
Background: Antipsychotic drug treatment can potentially lead to adverse events such as leukopenia and
neutropenia. Although these events are rare, they represent serious and life-threatening hematological side effects.
Case presentation: We present a case study of a patient with schizoaffective disorder in a 50-year-old woman. We
report a case of paliperidone extended-release (ER)-induced leukopenia and neutropenia in a female patient with
schizoaffective disorder. Initiating lithium carbonate treatment and decreasing the dose of valproic acid improved
the observed leukopenia and neutropenia. This treatment did not influence psychotic symptoms.
Conclusion: The combination of paliperidone ER and valproic acid induces increased paliperidone ER plasma levels.
Lithium carbonate was successfully used to treat paliperidone ER-induced leukopenia and neutropenia.
Keywords: Schizoaffective disorder, Schizophrenia, Paliperidone extended-release, Neutropenia, Leukopenia, Lithium
carbonate, Valproic acid
Background
Schizoaffective disorder refers to the coexistence of gen-
erally continuous schizophrenic symptoms plus inter-
mittent mood episodes. The dopamine hypothesis of
schizophrenia is attributable to the principal descriptive
model of antipsychotic drug action. However, leukopenia
and neutropenia are known to be serious adverse effects
of antipsychotic drug treatment. Although clozapine has
been most strongly associated with such events, similar
side effects have been reported with risperidone [1, 2],
olanzapine [3, 4], and quetiapine [5, 6]. Moreover, paliperi-
done extended-release (ER), which is chemically a major
active metabolite of risperidone (9-hydroxyrisperidone),
has also been found to elicit leukopenia and neutropenia
in rare cases [7, 8]. Leukopenia is characterized by a
decrease in the number of white blood cells, often due to
neutropenia. Neutropenia can be defined as a neutrophil
count of < 1.50 × 109/L. There are two well-known
treatment strategies: the adjuvant use of lithium
carbonate and granulocyte colony-stimulating factor
[9, 10]. No studies to date, however, have reported
the use of lithium carbonate in the case of paliperidone
ER-induced leukopenia and neutropenia.
Consequently, this report focuses on the use of lithium
carbonate in the treatment of paliperidone ER-induced
leukopenia and neutropenia in a female patient with
schizoaffective disorder. We believe our study to be
novel as a survey of the literature failed to identify any
current reports describing the use of lithium carbonate
in this setting.
Case presentation
Patient A is a 50-year-old woman who started to present
psychotic symptoms fulfilling DSM-IV-TR diagnostic
criteria for schizoaffective disorder at age 46 years. She
experienced positive symptoms (paranoid delusions and
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auditory hallucinations), as well as disorganized thinking
and behavior, and affective symptoms. There were
neither previous reports of premorbid symptoms, nor a
family history of psychosis, nor other mental disorders.
She has been hospitalized on three occasions owing to
exacerbation of psychotic symptoms. Two months after
the last hospitalization, she has again developed auditory
hallucinations and aggressive behavior despite taking
quetiapine 200 mg/day, olanzapine 10 mg/day, and
valproic acid 200 mg/day.
These symptoms had her admitted to the hospital
where the dosage amount was gradually increased to
quetiapine 200 mg/day, olanzapine 20 mg/day, and
valproic acid 1000 mg/day. At this point, a laboratory
assessment showed normal levels of white blood cell
(WBC; 4.04 × 109/L) and neutrophil counts (2.01 × 109/L),
respectively. The valproic acid plasma level was
70.6 mg/L. Since she still had refractory auditory
hallucinations in spite of active medications, paliperi-
done ER was added on at 28 days after admission
when WBC and neutrophil counts were 4.03 × 109/L
and 2.26 × 109/L, respectively. Then, dosage was
increased to 12 mg/day over 2 weeks. At 55 days, she
exhibited a sudden drop in WBC count (2.83 × 109/L)
and neutrophil count (0.79 × 109/L), while liver function
and renal function were both within normal levels.
Because of these sudden changes at day 55, paliperi-
done ER treatment was immediately stopped, the dose
of valproic acid was decreased to 600 mg/day, and
lithium carbonate was initiated (200 mg/day). At four
days after lithium carbonate administration, the blood
composition of the patient had returned to normal levels
(WBC count of 4.34 × 109/L, neutrophil count of
2.29 × 109/L). The valproic acid plasma level had
decreased to 32.8 mg/L. Twenty-eight days later, the
WBC count had increased to 6.86 × 109/L and the
neutrophil count was 4.74 × 109/L. Finally, lithium
carbonate was gradually decreased and stopped be-
cause neither leukopenia nor neutropenia were observed
over the following 6 months. She is currently stable
taking quetiapine 200 mg/day, olanzapine 20 mg/day,
and valproic acid 600 mg/day. Her symptoms have
not worsened any longer since the cessation of pali-
peridone ER therapy.
Discussion
To the best of our knowledge, no studies have yet reported
on paliperidone ER-induced neutropenia in patients with
schizoaffective disorder. Moreover, few studies have yet
reported on paliperidone ER- or combination paliperidone
ER and risperidone-induced neutropenia even in patients
with schizophrenia [7, 8]. The case presented here is the
first to demonstrate the therapeutic effect of add-on lithium
for paliperidone ER-induced neutropenia.
Unexpectedly, antipsychotic drugs have numerous ad-
verse effects, the most serious of which involve hematologic
toxicity such as leukopenia and neutropenia. While
these adverse effects are frequently occurred with clo-
zapine treatment [11], other antipsychotic drugs have
been found to induce similar side effects. Although the
pathophysiological mechanisms underlying antipsychotic-
induced neutropenia/leukopenia remain unknown, some
potential mechanisms have been proposed as follows:
direct bone marrow suppression, antibody formation
against hematologic precursors, and peripheral destruction
of cells [12].
In our patient, leukopenia and neutropenia were nor-
malized in 4 days after discontinuing paliperidone ER,
tapering valproate acid, and starting lithium carbonate.
Of course, we cannot exclude the possibility that we only
had to stop paliperidone ER and/or valproate acid
treatment to normalize leukopenia and neutropenia.
However, lithium carbonate treatment might be effica-
cious in shortening the time required for the recovery
from leukopenia and neutropenia [10]. Moreover, during
severe leukopenia and neutropenia, morbidity and risk
of mortality increases owing to the risk of infection and
the complications of infection. Therefore, the present
case suggests that administration of lithium carbonate
should be appropriate at an early stage.
The present case has important implications for the
safety of valproic acid as a potential causative agent of
the above-mentioned adverse effects, especially given
that a previous case study reported severe neutropenia
accompanied by valproic acid administration [13]. In our
case, valproic acid treatment could not be completely
discontinued due to her persistent affective symptoms
with aggressive behavior. However, valproic acid was
unlikely to be the causative agent as the patient had
been taking valproic acid prior to admission to the
hospital. Instead valproic acid might play a critical role
in combination with paliperidone ER because valproic
acid is known to increase paliperidone ER plasma levels
[14]. Alternatively, a combination pharmacotherapy itself
might be intricately involved with leukopenia and
neutropenia, while such phenomena had not been
observed before administration of paliperidone ER.
Overall, this case report suggests that paliperidone
ER-induced leukopenia and neutropenia might be
dose-dependent.
Conclusion
A 50-year-old female patient with schizoaffective dis-
order developed paliperidone ER-induced leukopenia
and neutropenia. Initiating lithium carbonate, discon-
tinuing paliperidone ER, and decreasing the dose of
valproic acid might reverse leukopenia and neutropenia.
This case strongly suggests that blood composition and
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other health indicators should be monitored carefully
when using antipsychotics including paliperidone ER,
especially combined therapy with valproic acid. More-
over, lithium carbonate should be considered in the
treatment of paliperidone ER-induced leukopenia and
neutropenia.
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